Sanofi’s shift to immunology, AI-driven R&D, and strong pipeline offset risks from patent cliffs and legal issues. See why ...

Digitization has allowed Sanofi to optimize manufacturing and automate document preparation. And now, the firm predicts that ...

In July, spending on TV ads for prescription drugs reached a low not seen since this time last year. | In July, spending on ...

Sanofi’s commitment to sustainability has been recognized globally, with TIME ranking it as the world’s 10th most sustainable company across all industries and #1 in pharma and biotech. This accolade ...

Regeneron topped Wall Street estimates for second-quarter results on Friday, on robust demand for its blockbuster eczema drug ...

REGN stock up as Q2 EPS jumps 12% on strong Eylea HD and Dupixent profits, beating revenue and earnings estimates.

Sanofi missed analyst projections of $1.32 with Q2 earnings per share (EPS) of $1.25. Revenue was €9.89 billion, which was ...

(Reuters) -Regeneron Pharmaceuticals beat Wall Street estimates for second-quarter revenue and profit on Friday helped by ...

Regeneron-partnered Dupixent, the crown jewel of Sanofi’s commercial portfolio, continued to impress with 21.1% sales growth ...

Sanofi expanded the sales reach of the drug with approvals in the lucrative chronic obstructive pulmonary disease (COPD) ...

For now, Sanofi’s U.S. inventory is insulating the company from a potential 15% tariff on drugs shipped from the EU.

Drugmaker Sanofi said on Thursday it believes the impact from U.S. tariffs to be manageable as it raised its sales growth ...